First time at Proteopedia? Click on the green links, they change the 3D image. Proteopedia is a 3D, interactive encyclopedia of proteins, RNA, DNA and other molecules. With a free user account, you can edit pages in Proteopedia. Visit the Main Page to learn more.
2vip
From Proteopedia
| 2vip, resolution 1.72Å () | |
|---|---|
| Sites: | , and |
| Ligands: | , , |
| Activity: | U-plasminogen activator, with EC number 3.4.21.73 |
| Domains: | Tryp_SPc |
| Related: | 2viv, 1c5x, 1gj9, 2vio, 1w0z, 1fv9, 1vja, 1gj8, 1w11, 1sqo, 1gjd, 1w10, 1owk, 1w12, 1gi9, 1o5a, 1c5z, 1owj, 1gi7, 1o5b, 1gjc, 1sc8, 1gja, 1o3p, 1owe, 1sqa, 1gjb, 2viw, 1f92, 1owi, 1kdu, 2vin, 1sqt, 1f5l, 1owd, 1ejn, 2viq, 1lmw, 1u6q, 1gi8, 2jde, 1c5y, 1w14, 1vj9, 1w13, 1gj7, 1c5w, 1owh, 1o5c |
| Resources: | FirstGlance, OCA, PDBsum, RCSB |
| Coordinates: | save as pdb, mmCIF, xml |
FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator., Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M, Wallis NG, J Med Chem. 2008 Jan 24;51(2):183-6. Epub 2007 Dec 29. PMID:18163548
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
About this Structure
2VIP is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator., Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M, Wallis NG, J Med Chem. 2008 Jan 24;51(2):183-6. Epub 2007 Dec 29. PMID:18163548
Page seeded by OCA on Sun Jul 27 22:00:38 2008
Categories: Homo sapiens | Single protein | U-plasminogen activator | Callaghan, O. | Chessari, G. | Congreve, M. | Cowan, S R. | Frederickson, M. | Matthews, J E. | Mcmenamin, R. | Smith, D. | Vinkovic, M. | Wallis, N G. | Blood coagulation | Egf-like domain | Fibrinolysis | Glycoprotein | Hydrolase | Inhibitor | Kringle | Pharmaceutical | Phosphorylation | Plasminogen activation | Polymorphism | Protease | Secreted | Serine protease | Urokinase-type plasminogen activator | Zymogen
